|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
87,300,000 |
Market
Cap: |
18.04(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.2066 - $0.2066 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, is a once-weekly prescription combination hormonal contraceptive patch. It delivers a dose of estrogen that is consistent with commonly prescribed combined hormonal contraceptives. Co.'s pipeline consists of two classes of product candidates: Co.'s potential product pipeline consists of two types of product candidates: a progestin-only contraceptive patch and potential Twirla line extensions. These potential product candidates are designed to address market needs and provide additional non-daily contraceptive options. Including AG200-15 Extended Regimen, AG200-SmP, and AG200-15 ER SmP.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gilmore Geoffrey |
General Counsel |
|
2020-03-13 |
4 |
A |
$1.56 |
$39,780 |
D/D |
25,500 |
81,283 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2020-03-13 |
4 |
B |
$1.75 |
$1,750,000 |
I/I |
1,000,000 |
15,919,925 |
1.5 |
- |
|
Reilly Dennis |
Chief Financial Officer |
|
2020-03-04 |
4 |
B |
$2.35 |
$58,750 |
I/I |
25,000 |
25,000 |
1.99 |
- |
|
Reilly Dennis |
Chief Financial Officer |
|
2020-03-04 |
4 |
B |
$2.32 |
$116,000 |
D/D |
50,000 |
59,806 |
2.74 |
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2020-02-27 |
4 |
B |
$2.71 |
$27,100 |
D/D |
10,000 |
311,611 |
2.81 |
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2020-02-27 |
4 |
OE |
$0.71 |
$11,744 |
D/D |
16,541 |
301,611 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2020-02-25 |
4 |
B |
$3.00 |
$9,000,000 |
I/I |
3,000,000 |
14,919,925 |
1.5 |
- |
|
Gilmore Geoffrey |
General Counsel |
|
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
10,071 |
55,783 |
|
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
26,502 |
285,070 |
|
- |
|
Reilly Dennis |
Chief Financial Officer |
|
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,806 |
9,806 |
|
- |
|
Conway Robert G |
Sr. VP Manufacturing & Supply |
|
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,272 |
12,547 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2019-11-15 |
4 |
B |
$1.60 |
$8,940,812 |
I/I |
5,333,800 |
11,919,925 |
1.5 |
- |
|
Edelman Joseph |
10% Owner |
|
2019-11-14 |
4 |
B |
$1.69 |
$735,175 |
I/I |
435,015 |
6,586,125 |
1.5 |
- |
|
Edelman Joseph |
10% Owner |
|
2019-10-29 |
4 |
S |
$0.44 |
$334,528 |
I/I |
(760,291) |
6,151,110 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2019-10-28 |
4 |
S |
$0.51 |
$1,945,828 |
I/I |
(3,815,349) |
6,911,401 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2019-08-06 |
4 |
B |
$0.95 |
$2,185,000 |
I/I |
2,300,000 |
10,726,750 |
1.5 |
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2019-06-10 |
4 |
B |
$1.27 |
$25,400 |
D/D |
20,000 |
258,568 |
2.81 |
- |
|
Lele Abhijeet J |
Director |
|
2019-03-29 |
4 |
B |
$1.54 |
$30,800 |
D/D |
20,000 |
37,949 |
2.39 |
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2019-03-25 |
4 |
B |
$1.54 |
$38,500 |
D/D |
25,000 |
238,568 |
2.81 |
- |
|
Edelman Joseph |
10% Owner |
|
2019-03-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,426,750 |
|
- |
|
Garner Elizabeth |
Sr. VP & Chief Medical Officer |
|
2019-01-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
47,800 |
|
- |
|
Gilmore Geoffrey |
General Counsel |
|
2019-01-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
45,712 |
|
- |
|
Coiante Scott M |
Chief Financial Officer |
|
2019-01-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
48,256 |
|
- |
|
Garner Elizabeth |
Sr. VP & Chief Medical Officer |
|
2019-01-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,565 |
30,300 |
|
- |
|
Altomari Alfred |
Chief Executive Officer |
|
2019-01-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,314 |
213,568 |
|
- |
|
116 Records found
|
|
Page 3 of 5 |
|
|